Mavoglurant (AFQ056)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Mavoglurant (AFQ056), covering 2025-10-09 to 2025-10-09. Get the full timeline:
Most recent: Clinical Trial Update: Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant [EARLY_Phase 1]